A First-in-Human, Phase 1/2 Study of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1) - Trial NCT06277219
Access comprehensive clinical trial information for NCT06277219 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by Latticon Antibody Therapeutics, Inc and is currently Not yet recruiting. The study focuses on Advanced Solid Tumor. Target enrollment is 150 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Latticon Antibody Therapeutics, Inc
Timeline & Enrollment
Phase 1/2
Mar 01, 2024
Mar 01, 2027
Primary Outcome
Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) (Phase 1),Incidence of changes in clinical laboratory values (Phase 1),Incidence of dose-limiting toxicities (DLTs) (Phase 1),Objective response rate (ORR) per RECIST 1.1 (Phase 2)
Summary
This is an open-label, multicenter, Phase 1/2, first-in-human (FIH), dose-escalation and
 cohort-expansion study of LAT010 to evaluate the safety, tolerability, immunogenicity, PK,
 PD, and antitumor activity in patients with advanced solid tumors. The study consists of 2
 parts: Phase 1 dose-escalation and Phase 2 cohort expansion.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06277219
Non-Device Trial